Skip to content

Study · Other design · 2023

10 results

Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.

Heller S, Battelino T, Bailey TS, Pieber TR, Hövelmann U, Plum-Mörschel L, Melgaard AE, Aronson R, DiMeglio LA, Johansen T, Danne T

Diabetes, obesity & metabolism14 Feb 2023Cited by 1 (Europe PMC)

PMID36692230 (opens in a new tab)DOI10.1111/dom.14987 (opens in a new tab)PepBankPUB-36692230
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanOther designSafety outcome

    In adults with type 1 diabetes, dasiglucagon had a safety and tolerability profile similar to reconstituted glucagon.

    In plain wordsIn adults with type 1 diabetes, dasiglucagon had similar safety and tolerability to reconstituted glucagon.

    Peptide
    Dasiglucagon
    Outcome
    Direction not reportedSafety and tolerability profile
    Study

    n: not reported in source

    Comparator
    Reconstituted glucagon
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dasiglucagon had a similar safety and tolerability profile to that of reconstituted glucagon.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  2. 02HumanOther designSafety outcome

    In the placebo-controlled datasets of adults with type 1 diabetes, no serious adverse events were reported with dasiglucagon.

    In plain wordsIn the placebo-controlled datasets, adults with type 1 diabetes had no reported serious adverse events with dasiglucagon.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the placebo-controlled datasets, no serious adverse events (AEs), AEs leading to withdrawal from the trial, or deaths were reported.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  3. 03HumanOther designSafety outcome

    In the placebo-controlled datasets of adults with type 1 diabetes, no adverse events leading to withdrawal were reported with dasiglucagon.

    In plain wordsIn the placebo-controlled datasets, no dasiglucagon adverse events led to trial withdrawal in adults with type 1 diabetes.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableAdverse events leading to withdrawal
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the placebo-controlled datasets, no serious adverse events (AEs), AEs leading to withdrawal from the trial, or deaths were reported.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  4. 04HumanOther designSafety outcome

    In the placebo-controlled datasets of adults with type 1 diabetes, no deaths were reported with dasiglucagon.

    In plain wordsIn the placebo-controlled datasets, no deaths were reported with dasiglucagon in adults with type 1 diabetes.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableDeaths
    Study

    n: not reported in source

    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the placebo-controlled datasets, no serious adverse events (AEs), AEs leading to withdrawal from the trial, or deaths were reported.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  5. 05HumanOther designSafety outcome

    In adults with type 1 diabetes, causally related nausea occurred in 56.5% in the dasiglucagon analysis.

    In plain wordsIn adults with type 1 diabetes, causally related nausea occurred in 56.5% in the dasiglucagon analysis.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Nausea
    56.5%
    causally related adverse events

    Source sentences

    Summary
    The most common causally related AEs were nausea (56.5%) and vomiting (24.6%).
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  6. 06HumanOther designSafety outcome

    In adults with type 1 diabetes, causally related vomiting occurred in 24.6% in the dasiglucagon analysis.

    In plain wordsIn adults with type 1 diabetes, causally related vomiting occurred in 24.6% in the dasiglucagon analysis.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Vomiting
    24.6%
    causally related adverse events

    Source sentences

    Summary
    The most common causally related AEs were nausea (56.5%) and vomiting (24.6%).
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  7. 07HumanOther designSafety outcome

    In adults with type 1 diabetes, the broad-pool dasiglucagon safety analysis showed results similar to the placebo-controlled pool.

    In plain wordsIn adults with type 1 diabetes, dasiglucagon safety results were similar across the broad and placebo-controlled pools.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableBroad pool safety profile
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The broad pool safety analysis showed similar results.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  8. 08HumanOther designEfficacy outcome

    In adults with type 1 diabetes, median recovery from insulin-induced severe hypoglycemia was similar with dasiglucagon and reconstituted glucagon: 10.0 versus 12.0 minutes.

    In plain wordsIn adults with type 1 diabetes, recovery time was similar with dasiglucagon and reconstituted glucagon: 10.0 versus 12.0 minutes.

    Peptide
    Dasiglucagon
    Outcome
    Direction not reportedTime to plasma glucose recovery
    Study

    n: not reported in source

    Comparator
    Reconstituted glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median recovery time
    10 minutes
    dasiglucagon
    Median recovery time
    12 minutes
    reconstituted glucagon

    Source sentences

    Summary
    Dasiglucagon efficacy in time to plasma glucose recovery from insulin-induced SH was similar to that of reconstituted glucagon (median 10.0 and 12.0 minutes, respectively) and superior to placebo (median 40.0 minutes; P < 0.0001).
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  9. 09HumanOther designEfficacy outcome

    In adults with type 1 diabetes, dasiglucagon shortened median recovery from insulin-induced severe hypoglycemia versus placebo: 10.0 versus 40.0 minutes, P < 0.0001.

    In plain wordsIn adults with type 1 diabetes, dasiglucagon shortened recovery from severe hypoglycemia compared with placebo: 10.0 versus 40.0 minutes.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime to plasma glucose recovery
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median recovery time
    10 minutes
    dasiglucagon
    Median recovery time
    40 minutes
    placebo

    Source sentences

    Summary
    Dasiglucagon efficacy in time to plasma glucose recovery from insulin-induced SH was similar to that of reconstituted glucagon (median 10.0 and 12.0 minutes, respectively) and superior to placebo (median 40.0 minutes; P < 0.0001).
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.
  10. 10HumanOther designEfficacy outcome

    In adults with type 1 diabetes, median dasiglucagon recovery time was consistent across all placebo-controlled trial subgroups.

    In plain wordsIn adults with type 1 diabetes, median dasiglucagon recovery time was consistent across all placebo-controlled trial subgroups.

    Peptide
    Dasiglucagon
    Outcome
    Direction not reportedRecovery time across subgroups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The median recovery time was consistent across all placebo-controlled trial subgroups.
    2 context sentences
    Summary · context
    An integrated analysis of dasiglucagon safety was conducted on data from two placebo-controlled trials (placebo-controlled pool) and two placebo-controlled and four non-placebo-controlled trials (broad pool) in adults with T1D.
    Summary · context
    An integrated analysis of dasiglucagon efficacy was conducted of pooled data and within demographic subgroups from the two placebo-controlled and two non-placebo-controlled trials in adults with T1D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.